Opiant Pharmaceuticals Inc (OPNT):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Opiant Pharmaceuticals Inc (OPNT) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7108
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:33
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Opiant Pharmaceuticals Inc (Opiant), formerly, Lightlake Therapeutics Inc is a specialty pharmaceutical company that develops pharmacological treatments for substance use, addiction and eating disorders. It focuses on developing treatments to reverse opioid overdoses, for overweight and obese patients with binge eating disorder (BED), and for cocaine use disorder. The company develops products based on its patented novel opioid antagonist nasal delivery technology. Opiant developed NARCAN (naloxone hydrochloride) nasal spray, a treatment to reverse opioid overdose. The product is approved for marketing in the US by its partner, Adapt Pharma. The company is also developing opioid antagonists with a near term focus on cocaine use disorder, binge eating disorder (BED) and bulimia nervosa. Opiant is headquartered in Santa Monica, California, the US.

Opiant Pharmaceuticals Inc (OPNT) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Opiant Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Opiant Pharmaceuticals Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Opiant Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Opiant Pharmaceuticals Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Opiant Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Opiant Pharmaceuticals Inc, Medical Equipment, Deal Details 10
Equity Offering 10
Opiant Pharma Raises USD13.8 Million in Public Offering of Shares 10
Opiant Pharma Raises USD12 Million in Public Offering of Shares 12
Opiant Pharma Raises USD5.3 Million in Private Placement of Shares up on Exercise of Warrants 13
Opiant Pharma Plans to Raise up to USD150 Million in Public Offering of Shares 14
Opiant Pharmaceuticals Inc – Key Competitors 15
Opiant Pharmaceuticals Inc – Key Employees 16
Opiant Pharmaceuticals Inc – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Financial Announcements 18
Aug 09, 2018: Opiant Pharmaceuticals reports second quarter 2018 financial results and provides corporate update 18
May 08, 2018: Opiant Pharmaceuticals Announces First Quarter 2018 Financial Results 20
Mar 07, 2018: Opiant Pharmaceuticals Reports Financial Results for August 1, 2017, Through December 31, 2017, and Provides Corporate Update 21
Dec 04, 2017: Opiant Pharmaceuticals Reports Fiscal First Quarter 2018 Financial Results 22
Oct 13, 2017: Opiant Pharmaceuticals Reports Fiscal Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 23
Jun 15, 2017: Opiant Pharmaceuticals Reports Fiscal Third Quarter 2017 Financial Results and Provides Corporate Update 25
Mar 16, 2017: Opiant Pharmaceuticals Reports Fiscal Second Quarter 2017 Financial Results and Provides Corporate Update 27
Research And Development 28
Sep 12, 2018: Consort to develop delivery device for opioid overdose drug 28
Corporate Communications 29
Jun 12, 2018: Opiant Pharmaceuticals Names Richard Daly As Board Director 29
Sep 05, 2017: Opiant Pharmaceuticals Announces Appointment of David O’Toole as Chief Financial Officer 30
Feb 06, 2017: Opiant Pharmaceuticals Announces the Appointment of Dr. Phil Skolnick as Chief Scientific Officer 31
Legal and Regulatory 32
Aug 28, 2017: Opiant Pharmaceuticals Announces Listing on the Nasdaq Capital Market 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
Opiant Pharmaceuticals Inc, Medical Equipment, Key Facts, 2017 2
Opiant Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Opiant Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Opiant Pharmaceuticals Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Opiant Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Opiant Pharmaceuticals Inc, Deals By Market, 2012 to YTD 2018 8
Opiant Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Opiant Pharma Raises USD13.8 Million in Public Offering of Shares 10
Opiant Pharma Raises USD12 Million in Public Offering of Shares 12
Opiant Pharma Raises USD5.3 Million in Private Placement of Shares up on Exercise of Warrants 13
Opiant Pharma Plans to Raise up to USD150 Million in Public Offering of Shares 14
Opiant Pharmaceuticals Inc, Key Competitors 15
Opiant Pharmaceuticals Inc, Key Employees 16
Opiant Pharmaceuticals Inc, Subsidiaries 17

List of Figures
Opiant Pharmaceuticals Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Opiant Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Opiant Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Opiant Pharmaceuticals Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Opiant Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Opiant Pharmaceuticals Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Opiant Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Opiant Pharmaceuticals Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[Opiant Pharmaceuticals Inc (OPNT):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Echelon Corporation:企業の戦略的SWOT分析
    Echelon Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Oaks Hotels & Resorts Limited:企業の戦略・SWOT・財務分析
    Oaks Hotels & Resorts Limited - Strategy, SWOT and Corporate Finance Report Summary Oaks Hotels & Resorts Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Tokuyama Corp (4043):電力:M&Aディール及び事業提携情報
    Summary Tokuyama Corp (Tokuyama), formerly Nihon Soda Kogyo Co., Ltd., manufactures and sells chemicals, specialty products and cement. Its product portfolio includes soda ash, caustic soda, silicon products, vinyl chloride monomer/polymer, fine chemicals, film products, medical materials, methylene …
  • City Developments Ltd
    City Developments Ltd - Strategy, SWOT and Corporate Finance Report Summary City Developments Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Sonoco Products Co (SON):企業の財務・戦略的SWOT分析
    Sonoco Products Co (SON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Coslight Technology International Group Ltd (1043):企業の財務・戦略的SWOT分析
    Coslight Technology International Group Ltd (1043) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • Housing Development & Infrastructure Ltd:企業の戦略・SWOT・財務情報
    Housing Development & Infrastructure Ltd - Strategy, SWOT and Corporate Finance Report Summary Housing Development & Infrastructure Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Middlesex Water Company (MSEX):企業の財務・戦略的SWOT分析
    Summary Middlesex Water Company (Middlesex Water) is a provider of water utility services. The company's services include water production, treatment and distribution, regulated and non-regulated water and wastewater utility services, wastewater system maintenance and working to promote economic dev …
  • Weizmann Institute of Science:製薬・医療:M&Aディール及び事業提携情報
    Summary Weizmann Institute of Science (WIS) is a research institute that offers research activities in the field of natural and exact sciences. The institute provides programs that include graduate programs, post graduate programs, scientific research, academic affairs, science education, research a …
  • PUMA SE:企業の戦略・SWOT・財務情報
    PUMA SE - Strategy, SWOT and Corporate Finance Report Summary PUMA SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Television Francaise 1 SA (TFI):企業の財務・戦略的SWOT分析
    Television Francaise 1 SA (TFI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Aaron’s Inc:企業の戦略・SWOT・財務分析
    Aaron's Inc - Strategy, SWOT and Corporate Finance Report Summary Aaron's Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • ReShape Lifesciences Inc (RSLS):医療機器:M&Aディール及び事業提携情報
    Summary ReShape Lifesciences Inc (ReShape), formerly known as EnteroMedics Inc is a medical device company that develops minimally invasive medical devices to treat obesity and metabolic diseases. The company develops vBloc, a therapy used in the treatment of gastrointestinal and neurometabolic dise …
  • CPI Aerostructures, Inc.:企業の戦略・SWOT・財務情報
    CPI Aerostructures, Inc. - Strategy, SWOT and Corporate Finance Report Summary CPI Aerostructures, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Heptares Therapeutics Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Heptares Therapeutics Ltd (Heptares), a subsidiary of Sosei Group Corp is a drug discovery company that develops small-molecule drugs. The company develops drugs for targeting G-protein-coupled receptors by utilizing its drug discovery technology platforms. Its technology platforms comprise …
  • Software AG:企業の戦略・SWOT・財務情報
    Software AG - Strategy, SWOT and Corporate Finance Report Summary Software AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Cathay Pacific Airways Limited:企業のM&A・事業提携・投資動向
    Cathay Pacific Airways Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Cathay Pacific Airways Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • Tanzania Electric Supply Co Ltd:発電所・企業SWOT分析
    Tanzania Electric Supply Co Ltd - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on k …
  • Galp Energia SGPS SA (GALP)-エネルギー分野:企業M&A・提携分析
    Summary Galp Energia SGPS S.A. (Galp Energia) is an integrated oil and natural gas company. It explores for, develops and produces crude oil and natural gas; refines crude oil and markets refined petroleum products. The company also imports, transports and distributes natural gas. It conducts the na …
  • Jadason Enterprises Limited (J03):企業の財務・戦略的SWOT分析
    Jadason Enterprises Limited (J03) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆